WO2004031238A3 - Antibodies and cyclic peptides which bind cea (carcinoembryonic antigen) and their use as cancer therapeutics - Google Patents

Antibodies and cyclic peptides which bind cea (carcinoembryonic antigen) and their use as cancer therapeutics Download PDF

Info

Publication number
WO2004031238A3
WO2004031238A3 PCT/CA2003/001533 CA0301533W WO2004031238A3 WO 2004031238 A3 WO2004031238 A3 WO 2004031238A3 CA 0301533 W CA0301533 W CA 0301533W WO 2004031238 A3 WO2004031238 A3 WO 2004031238A3
Authority
WO
WIPO (PCT)
Prior art keywords
cea
relates
ceacam6
mediated
reversing
Prior art date
Application number
PCT/CA2003/001533
Other languages
French (fr)
Other versions
WO2004031238A2 (en
Inventor
Clifford P Stanners
Christian Ilantzis
Original Assignee
Mcgill Univeristy
Clifford P Stanners
Christian Ilantzis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mcgill Univeristy, Clifford P Stanners, Christian Ilantzis filed Critical Mcgill Univeristy
Priority to CA002500978A priority Critical patent/CA2500978A1/en
Priority to EP03769082A priority patent/EP1554309A2/en
Priority to AU2003278002A priority patent/AU2003278002A1/en
Publication of WO2004031238A2 publication Critical patent/WO2004031238A2/en
Publication of WO2004031238A3 publication Critical patent/WO2004031238A3/en
Priority to US11/097,224 priority patent/US20060024314A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Abstract

The present invention relates to differentiation and tumorigenicity. The present invention more particularly relates to ligands which target CEA and CEACAM6 such that the adhesion, differentiation-Inhibitory activities and tumorigenic effects of Ig superfamily members, CEA and CEACAM6, can be reduced or blocked. More particularly, the present invention relates to CEA-binding agents which reverse CEA-mediated tumorigenic effects by declustering CEA and CEACAM6. In one embodiment the invention relates to methods of reducing, preventing or reversing a CEA-mediated tumorigenic effect comprising a use of a CEA-mediated tumorigenic effect reducing CEA-declustering agent. In one embodiment, the invention relates to compositions and use thereof for reversing CEA-mediated tumorigenic effects on human cancer cells and uses thereof. In particular, the application relates to a monovalent CEA binding agent which interfereswith a CEA interaction responsible for a CEA-mediated tumorigenic effects, thereby minimizing or reversing same.
PCT/CA2003/001533 1998-02-12 2003-10-03 Antibodies and cyclic peptides which bind cea (carcinoembryonic antigen) and their use as cancer therapeutics WO2004031238A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002500978A CA2500978A1 (en) 2002-10-03 2003-10-03 Antibodies and cyclic peptides which bind cea (carcinoembryonic antigen) and their use as cancer therapeutics
EP03769082A EP1554309A2 (en) 2002-10-03 2003-10-03 Antibodies and cyclic peptides which bind cea (carcinoembryonic antigen) and their use as cancer therapeutics
AU2003278002A AU2003278002A1 (en) 2002-10-03 2003-10-03 Antibodies and cyclic peptides which bind cea (carcinoembryonic antigen) and their use as cancer therapeutics
US11/097,224 US20060024314A1 (en) 1998-02-12 2005-04-04 Antibodies and cyclic peptides which bind CEA (carcinoembryonic antigens) and their use as cancer therapeutics

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41552002P 2002-10-03 2002-10-03
US60/415,520 2002-10-03

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/097,224 Continuation US20060024314A1 (en) 1998-02-12 2005-04-04 Antibodies and cyclic peptides which bind CEA (carcinoembryonic antigens) and their use as cancer therapeutics

Publications (2)

Publication Number Publication Date
WO2004031238A2 WO2004031238A2 (en) 2004-04-15
WO2004031238A3 true WO2004031238A3 (en) 2004-07-29

Family

ID=32069871

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2003/001533 WO2004031238A2 (en) 1998-02-12 2003-10-03 Antibodies and cyclic peptides which bind cea (carcinoembryonic antigen) and their use as cancer therapeutics

Country Status (4)

Country Link
EP (1) EP1554309A2 (en)
AU (1) AU2003278002A1 (en)
CA (1) CA2500978A1 (en)
WO (1) WO2004031238A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG149815A1 (en) 2003-11-06 2009-02-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
EP2369350B1 (en) * 2004-04-20 2014-08-20 SphingoTec GmbH Use of precursors of tachykinins and/or their fragments in medical diagnostic
MXPA06014065A (en) 2004-06-01 2007-01-31 Genentech Inc Antibody drug conjugates and methods.
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
CN101065151B (en) 2004-09-23 2014-12-10 健泰科生物技术公司 Cysteine engineered antibodies and conjugates
IN2012DN03025A (en) 2009-09-09 2015-07-31 Ct Se Llc
EA024730B1 (en) 2010-04-15 2016-10-31 Медимьюн Лимитед Pyrrolobenzodiazepine compounds, conjugates thereof, pharmaceutical compositions comprising said conjugates, and use of said conjugates
KR101839163B1 (en) 2010-06-08 2018-03-15 제넨테크, 인크. Cysteine engineered antibodies and conjugates
WO2012074757A1 (en) 2010-11-17 2012-06-07 Genentech, Inc. Alaninyl maytansinol antibody conjugates
CA2833212C (en) 2011-05-12 2020-06-09 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides
KR101877598B1 (en) 2011-10-14 2018-07-11 메디뮨 리미티드 Pyrrolobenzodiazepines and conjugates thereof
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
ES2680153T3 (en) 2012-10-12 2018-09-04 Adc Therapeutics Sa Anti-PSMA-pyrrolobenzodiazepine antibody conjugates
US10695433B2 (en) 2012-10-12 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP2906251B1 (en) 2012-10-12 2017-09-27 ADC Therapeutics SA Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
EP2906296B1 (en) 2012-10-12 2018-03-21 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
HUE042731T2 (en) 2012-10-12 2019-07-29 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
TR201815418T4 (en) 2012-10-12 2018-11-21 Adc Therapeutics Sa Pyrrolobenzodiazepine -anti-psma antibody conjugates.
LT2839860T (en) 2012-10-12 2019-07-10 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9821074B2 (en) 2013-03-13 2017-11-21 Genentech, Inc. Pyrrolobenzodiazepines and conjugates thereof
CA2905181C (en) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
KR102066318B1 (en) 2013-03-13 2020-01-14 메디뮨 리미티드 Pyrrolobenzodiazepines and conjugates thereof
TWI636792B (en) 2013-08-12 2018-10-01 建南德克公司 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
WO2015052535A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2015052532A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
CN105828840B (en) 2013-12-16 2020-08-04 基因泰克公司 1- (chloromethyl) -2, 3-dihydro-1H-benzo [ e ] indole dimer antibody-drug conjugate compounds and methods of use and treatment
JP6671292B2 (en) 2013-12-16 2020-03-25 ジェネンテック， インコーポレイテッド Peptidomimetic compounds and antibody-drug conjugates thereof
CN107106700B (en) 2013-12-16 2020-10-30 基因泰克公司 Peptidomimetic compounds and antibody-drug conjugates thereof
WO2016037644A1 (en) 2014-09-10 2016-03-17 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
EP3191521A2 (en) 2014-09-12 2017-07-19 F. Hoffmann-La Roche AG Cysteine engineered antibodies and conjugates
CN106714844B (en) 2014-09-12 2022-08-05 基因泰克公司 Anthracycline disulfide intermediates, antibody-drug conjugates and methods
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
EP3235820A1 (en) 2014-09-17 2017-10-25 Genentech, Inc. Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
AU2015352545B2 (en) 2014-11-25 2020-10-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
WO2016090050A1 (en) 2014-12-03 2016-06-09 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
MA43345A (en) 2015-10-02 2018-08-08 Hoffmann La Roche PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
MA43354A (en) 2015-10-16 2018-08-22 Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
MA45326A (en) 2015-10-20 2018-08-29 Genentech Inc CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN108700598A (en) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 The drug of the total antibody of multichannel and antibody conjugate quantifies measuring method
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
PL3458101T3 (en) 2016-05-20 2021-05-31 F. Hoffmann-La Roche Ag Protac antibody conjugates and methods of use
EP3465221B1 (en) 2016-05-27 2020-07-22 H. Hoffnabb-La Roche Ag Bioanalytical method for the characterization of site-specific antibody-drug conjugates
JP7043425B2 (en) 2016-06-06 2022-03-29 ジェネンテック， インコーポレイテッド Silvestrol Antibodies-Drug Conjugates and Usage
EP3496763A1 (en) 2016-08-11 2019-06-19 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
JP7050770B2 (en) 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Method for preparing antibody drug conjugate
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
LT3544636T (en) 2017-02-08 2021-06-25 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
EP3612537B1 (en) 2017-04-18 2022-07-13 Medimmune Limited Pyrrolobenzodiazepine conjugates
WO2018193102A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
UA127900C2 (en) 2017-06-14 2024-02-07 Ейдісі Терапьютікс Са Dosage regimes for the administration of an anti-cd19 adc
MX2020001880A (en) 2017-08-18 2021-07-06 Medimmune Ltd Pyrrolobenzodiazepine conjugates.
WO2019060398A1 (en) 2017-09-20 2019-03-28 Ph Pharma Co., Ltd. Thailanstatin analogs
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
EP3870235A1 (en) 2018-10-24 2021-09-01 F. Hoffmann-La Roche AG Conjugated chemical inducers of degradation and methods of use
CN113227119A (en) 2018-12-10 2021-08-06 基因泰克公司 Photocrosslinked peptides for site-specific conjugation to Fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0584368A1 (en) * 1992-02-14 1994-03-02 Suntory Limited Cell adhesion inhibiting antibody and cell adhesion inhibitor containing the same
WO1998025971A1 (en) * 1996-12-10 1998-06-18 Celltech Therapeutics Limited Monovalent antibody fragments
US5872215A (en) * 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
WO1999041370A1 (en) * 1998-02-12 1999-08-19 Mcgill University Cea/nca-based differentiation cancer therapy
WO2001074849A2 (en) * 2000-04-03 2001-10-11 Dyax Corp. Binding peptides for carcinoembryonic antigen (cea)
US20020052479A1 (en) * 1996-10-31 2002-05-02 Kerr W.H. Anderson High affinity humanized anit-cea monoclonal antibodies
WO2002076389A2 (en) * 2001-03-21 2002-10-03 The Trustees Of Boston University Compositions and methods to prevent metastasis from primary malignancies

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5872215A (en) * 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
EP0584368A1 (en) * 1992-02-14 1994-03-02 Suntory Limited Cell adhesion inhibiting antibody and cell adhesion inhibitor containing the same
US20020052479A1 (en) * 1996-10-31 2002-05-02 Kerr W.H. Anderson High affinity humanized anit-cea monoclonal antibodies
WO1998025971A1 (en) * 1996-12-10 1998-06-18 Celltech Therapeutics Limited Monovalent antibody fragments
WO1999041370A1 (en) * 1998-02-12 1999-08-19 Mcgill University Cea/nca-based differentiation cancer therapy
WO2001074849A2 (en) * 2000-04-03 2001-10-11 Dyax Corp. Binding peptides for carcinoembryonic antigen (cea)
WO2002076389A2 (en) * 2001-03-21 2002-10-03 The Trustees Of Boston University Compositions and methods to prevent metastasis from primary malignancies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KUROKI M ET AL: "BIOCHEMICAL CHARACTERIZATION OF 25 DISTINCT CARCINOEMBRYONIC ANTIGEN (CEA) EPITOPES RECOGNIZED BY 57 MONOCLONAL ANTIBODIES AND CATEGORIZED INTO SEVEN GROUPS IN TERMS OF DOMAIN STRUCTURE OF THE CEA MOLECULE", HYBRIDOMA, LIEBERT, NEW YORK, NY, US, vol. 11, no. 4, 1992, pages 391 - 407, XP000606978, ISSN: 0272-457X *
PEDLEY R B ET AL: "THE POTENTIAL FOR ENHANCED TUMOUR LOCALISATION BY POLY(ETHYLENE GLYCOL) MODIFICATION OF ANTI-CEA ANTIBODY", BRITISH JOURNAL OF CANCER, LONDON, GB, vol. 70, 1994, pages 1126 - 1130, XP000575990, ISSN: 0007-0920 *
TAHERI M. ET. AL.: "Identification of precise subdomains in carcinoembryonic antigen required for intracellular adhesion", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 35, September 2001 (2001-09-01), pages 26935 - 26943, XP002277780 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Also Published As

Publication number Publication date
EP1554309A2 (en) 2005-07-20
AU2003278002A1 (en) 2004-04-23
AU2003278002A8 (en) 2004-04-23
WO2004031238A2 (en) 2004-04-15
CA2500978A1 (en) 2004-04-15

Similar Documents

Publication Publication Date Title
WO2004031238A3 (en) Antibodies and cyclic peptides which bind cea (carcinoembryonic antigen) and their use as cancer therapeutics
WO2002090566A3 (en) Recombinant tumor specific antibody and use thereof
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
WO2004076644A3 (en) A composition for delivering an agent to a target cell and uses thereof
WO2004006847A3 (en) Selected antibodies and duramycin peptides binding to anionic phospholipids and aminophospholipids and their use in treating viral infections and cancer
AU2001233027A1 (en) Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
WO2003048328A3 (en) Antibodies against carboxic anhydrase ix (ca ix) tumor antigen
IL214325A (en) Anti-cmet antibody, composition comprising it and use thereof
WO2006029219A3 (en) Human monoclonal anti-ctla4 antibodies in cancer treatment
WO2004010947A3 (en) Humanized antibodies against human 4-1bb
GEP20074091B (en) Cripto blocking antibodies and uses thereof
WO2005035572A3 (en) Antibody compositions and methods
EP2196474A3 (en) Therapeutic targets in cancer
EP2365005A3 (en) Novel anti-IGF-IR antibodies and uses thereof
WO2005090406A3 (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
WO2006038208A3 (en) Agents capable of downregulating an msf-a - dependent hif-1α and use thereof in cancer treatment
GR3026219T3 (en) Mouse monoclonal antibodies
WO2001098357A3 (en) Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations
ATE290879T1 (en) THERAPEUTIC ANTIBODIES AGAINST THE MUC-1 ANTIGEN AND METHOD FOR USE THEREOF
WO2005016241A3 (en) Synthetic chemokine receptor ligands and methods of use thereof
MXPA05013667A (en) Dual component skin care compositions that comprise a self-tanning agent.
WO2003045309A3 (en) Peptides, peptide compositions,and methods of use in binding p 185
WO2004035742A3 (en) Sets of digital antibodies directed against short epitopes, and methods using same
AU2407899A (en) Monoclonal antibody which recognizes the oligosaccharide n-glycolylated-galactose-glucose sialic acid in malignant tumors, and composition containing it
WO2007075706A3 (en) Affinity optimized epha2 agonistic antibodies and methods of use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2500978

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 11097224

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2003769082

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003769082

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11097224

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2003769082

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP